Clinical Trials for Uterine Cancer

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic NSCLC, melanoma, endometrial cancer, or HNSCC who have progressed after standard therapies including prior anti-PD-1/L1 agents, and evaluates the combination of STC-15 (an oral METTL3 inhibitor targeting RNA methylation) plus toripalimab (anti-PD-1 antibody). Eligible patients must have measurable disease, ECOG 0–1, and no active CNS disease.

ClinicalTrials.gov ID: NCT06975293

AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with unresectable or metastatic AKT1 E17K-mutant solid tumors who have progressed on, cannot tolerate, or declined appropriate standard therapy receive continuous oral ALTA2618. This investigational inhibitor is designed to bind mutant AKT1 E17K allosterically and covalently while largely sparing wild-type AKT.

ClinicalTrials.gov ID: NCT06533059

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory DLL3-expressing or DLL3-prevalent tumors (including SCLC, LCNEC, high-grade neuroendocrine tumors, and select NSCLC/other histologies) receive the DLL3-directed bispecific T‑cell engager tarlatamab plus external-beam radiation, given concurrently or sequentially depending on safety. Key risks include CRS/ICANS; includes extracranial and cranial RT cohorts with allowance for treated/stable brain mets and selected brain lesions.

ClinicalTrials.gov ID: NCT06814496

A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with measurable, folate receptor-α–positive persistent/recurrent endometrial cancer (including uterine serous, grade 2–3 endometrioid, carcinosarcoma with high-grade serous or grade 2/3 endometrioid components, and clear cell), ECOG 0–1, and ≤3 prior lines for recurrence. Patients receive mirvetuximab soravtansine, an FRα-targeted antibody–drug conjugate delivering the DM4 microtubule inhibitor, IV every 3 weeks until progression or toxicity.

ClinicalTrials.gov ID: NCT03832361

Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or recurrent endometrial cancer (multiple histologies) after ≥1 prior cytotoxic line, ECOG 0–2, receive atezolizumab (PD‑L1 inhibitor) plus ONC201/dordaviprone, an investigational DRD2 antagonist and ClpP agonist that activates the integrated stress response to promote tumor apoptosis and immunogenicity. Nonrandomized dose-finding with expansion; cohorts stratified by obesity (BMI >30 vs ≤29.9); prior PD-(L)1 or ONC201 not allowed.

ClinicalTrials.gov ID: NCT05542407

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent or persistent epithelial cervical cancer after ≥1 prior systemic chemotherapy (up to two for recurrence allowed), ECOG 0–1, and available archival tissue for TROP-2 testing receive sacituzumab govitecan 10 mg/kg IV D1,8 q21d until progression/toxicity. Sacituzumab govitecan is a Trop-2–targeted antibody–drug conjugate delivering SN-38 (topoisomerase I inhibitor); prior immunotherapy allowed, but exclude prior topo I inhibitors, active CNS mets, bulky >7 cm (unless PI-approved), significant comorbidities, and viral infections with detectable load.

ClinicalTrials.gov ID: NCT05838521

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adult women with recurrent gynecologic carcinosarcoma after at least one prior systemic regimen (ECOG 0–2), this single-arm study gives cabozantinib (oral MET/VEGFR2/AXL multikinase inhibitor) plus dostarlimab (anti–PD-1) with maintenance dosing. Key exclusions include prior cabozantinib, unstable CNS disease, significant bleeding/GI risk, uncontrolled CV/HTN, active autoimmune disease requiring systemic therapy, and contraindicated anticoagulation.

ClinicalTrials.gov ID: NCT05559879

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adult women with histologically confirmed locally advanced or metastatic cervical cancer that has progressed or been intolerant to ≥1 prior systemic therapy, with measurable disease and ECOG 0–1. Patients receive pembrolizumab (PD‑1 inhibitor) plus lenvatinib (oral multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT) aiming to enhance antitumor immunity by counteracting VEGF-mediated immunosuppression.

ClinicalTrials.gov ID: NCT04865887

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with TP53 wild-type advanced or recurrent endometrial carcinoma (endometrioid, serous, undifferentiated, or carcinosarcoma) who achieved CR/PR after at least 12 weeks of first-line platinum therapy are randomized to maintenance selinexor vs placebo. Selinexor is an oral exportin 1 (XPO1) inhibitor that promotes nuclear retention/reactivation of tumor suppressors; treatment is 60 mg once weekly on a 28-day cycle.

ClinicalTrials.gov ID: NCT05611931

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/persistent RAS-pathway–mutant ovarian, fallopian tube, primary peritoneal, or endometrial cancers (KRAS/NRAS/HRAS/BRAF/MEK1/MEK2 activating or NF1 loss), measurable and biopsiable, are randomized to selumetinib (MEK1/2 inhibitor) plus olaparib (PARP inhibitor) versus selumetinib alone; ovarian patients must be platinum-ineligible and endometrial patients should have received or been offered immunotherapy (± lenvatinib). No prior MEK inhibitors or progression on PARP allowed; crossover to the combination is permitted at progression from selumetinib monotherapy.

ClinicalTrials.gov ID: NCT05554328